Alcohol is estimated to be a factor in 35% of driver fatalities in Ireland (toxicology data, RSA 2016–2020). Drug-driving arrests exceeded 8,800 in 2023. This guide covers the pharmacology of impairment, the BAC-crash risk relationship, Irish law, drug categories, and what the enforcement data tells us.
Alcohol (ethanol) is a CNS depressant acting primarily on GABA-A receptors to produce inhibitory effects, and on glutamate receptors to suppress excitatory signals. Its effects on the specific cognitive systems required for driving are well-characterised.
Driving requires continuous simultaneous processing — monitoring speed, tracking lanes, scanning junctions, processing signs. Even sub-legal BAC levels (0.02–0.05%) measurably degrade divided attention performance in controlled laboratory studies.
At 0.08% BAC, simple reaction time increases by approximately 15–25% compared to sober baseline. More critically, complex reaction time — responding to unexpected stimuli — degrades disproportionately at the same BAC level.
Alcohol impairs the brain's ability to assess risk accurately at very low doses. The orbitofrontal cortex, responsible for evaluating consequences, is among the first structures affected — producing the well-documented paradox of overconfidence in impaired drivers.
At 0.08% BAC, useful field of view (UFOV) narrows by approximately 35°. Peripheral vision — critical for detecting vehicles at junctions and pedestrians at the roadside — is significantly degraded even while central vision appears unaffected to the driver.
Standard deviation of lateral position (SDLP), the primary metric of lane-keeping performance in driving simulators, increases measurably from 0.04% BAC. At 0.08%, SDLP is significantly elevated — equivalent to moderate drowsiness.
Alcohol uniquely impairs the ability to judge one's own impairment. Studies show that at BACs of 0.08–0.10%, drivers typically rate their own driving ability as unchanged or improved compared to sober baseline. This is pharmacologically driven, not simply denial.
The seminal Borkenstein Grand Rapids Study (1964, replicated 1999) established the non-linear relationship between BAC and relative crash risk. The curve rises slowly at first, then exponentially above 0.08%.
Some performance degradation detectable in laboratory conditions. Below the limit for professional drivers in some EU states. Divided attention and SDLP begin to show statistically significant changes.
Ireland's current legal limit for learner/novice drivers and professional drivers. EU majority limit. Significant impairment in complex tasks measurable. Lower limit justified by the evidence at this level.
Ireland's general driving limit. Above this level: lane deviation, reaction time, gap acceptance and risk compensation are all significantly impaired. Risk is 2.5–3× that of a sober driver across multiple studies.
Substantially above legal limits. Steering errors visible; speed regulation impaired; braking decisions compromised. Crash risk escalates steeply — at 0.15%, relative risk is approximately 7× sober (Borkenstein, replicated Blomberg 2005).
Extreme impairment. At 0.20%, relative crash risk has been modelled at 13–25× sober. At these levels, motor coordination, speech, balance, and visual processing are severely affected. Fatally dangerous.
The EU DRUID project (2006–2011), involving 23 European countries and over 50,000 subjects, is the largest study of drugs and driving. It established crash risk multipliers for different drug categories by comparing prevalence in crashed drivers versus non-crashed control populations.
THC impairs divided attention, lane-tracking, and speed regulation. Peak impairment within 30 min of smoking; persists 3–4 hours. Driver typically underestimates speed. DRUID found OR of 1.83–2.51 depending on THC level. Commonly combined with alcohol (multiplicative risk).
Cocaine produces overconfidence, aggressive driving, risk-taking, and impaired impulse control. The rebound "crash" phase produces fatigue indistinguishable from sleep deprivation. Amphetamine produces similar effects with longer duration.
Prescription CNS depressants. Produce sedation, slowed reaction time, anterograde amnesia (reduced hazard memory), and impaired coordination. Risk is highest with long-acting agents and in older drivers. Over-the-counter sedating antihistamines carry similar risk.
Both illicit opioids (heroin) and prescribed opioids (codeine, tramadol) impair reaction time and hazard perception. Long-term methadone users on stable doses show significantly less impairment than acute opioid users — though impairment persists.
The combination of alcohol and cannabis produces super-additive (multiplicative, not additive) impairment. DRUID found OR of 14.1 for this combination — the single most dangerous drug combination identified in the study.
EU Directive 2006/126/EC identifies 30+ medication categories that may impair driving. Prescribers have a duty to warn. Patients have a responsibility to check. Always check the Patient Information Leaflet — "drowsiness" warning means do not drive.
Official data from the RSA, Medical Bureau of Road Safety (MBRS), and An Garda Síochána provides a clear picture of alcohol and drug driving prevalence and trends in Ireland.
RSA analysis of coronial data 2016–2020: 35% of drivers with toxicology results available tested positive for alcohol. Figures for motorcycle rider fatalities are even higher.
Of driver fatalities occurring between 10pm and 6am, 70% tested positive for alcohol — demonstrating the extreme concentration of impaired driving in nighttime hours (RSA coronial data).
Total drink and drug-driving arrests in Ireland in 2023, per Garda enforcement records. This includes mandatory alcohol testing (MAT) checkpoints and drug-impairment testing by Drug Recognition Experts (DREs).
E-Survey of Road Users' Attitudes (ESRA 2023): 9% of Irish drivers admitted to driving within one hour of taking recreational drugs in the previous 30 days — above the EU average of 7%.
RSA national survey (January 2024): 1 in 10 Irish drivers admitted to driving after consuming alcohol in the previous 12 months, despite drink-driving being among the most publicly condemned behaviours.
Older RSA analysis covering both driver/motorcyclist (38%) and pedestrian (9%) alcohol-positive fatalities. Pedestrian fatalities involving alcohol are frequently invisible in public awareness campaigns.
Ireland's drink-driving law is governed by the Road Traffic Act 2010 as amended. Three separate BAC limits apply depending on the driver category, with graduated penalty structures.
Ireland's general limit. Breath equivalent: 35μg per 100ml. The highest limit currently permitted under EU guidance — the EU recommends 50mg/100ml as best practice for all drivers.
80–100mg: 3 penalty points + fine. 100mg+: mandatory court, disqualificationApplies to holders of learner permits and drivers who have held a full licence for less than 2 years (N-plate). Aligned with EU best practice. Enforced through same Garda MAT checkpoint network.
50–80mg: 3 penalty points + fine. 80mg+: mandatory courtApplies to HGV and PSV licence holders when driving a vehicle requiring Cat C or D licence. Effectively a near-zero limit. Enforcement at RSA roadside checkpoints alongside tachograph compliance checks.
Any exceedance: mandatory court, licence suspension, employer notificationIt is an offence to drive while under the influence of an intoxicant (including drugs) to such an extent as to be incapable of having proper control. Drug Recognition Experts (DREs) conduct 12-step evaluation following positive preliminary impairment test.
Conviction: disqualification, fine, potential imprisonmentAn Garda Síochána may require a breath test at a MAT checkpoint without any requirement to show grounds for suspicion. This is distinct from the UK roadside system and is the primary enforcement mechanism in Ireland.
Refusal to provide breath sample: same penalty as failing testThe MBRS provides confirmatory testing for all cases proceeding to prosecution. Annual MBRS reports publish detailed breakdown of positive samples by substance type — providing Ireland's most reliable drug-driving prevalence data.
MBRS certificate is admissible as evidence in court under RTA 2010